World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0003345072
Reproduction Date:

Title: Tipranavir  
Author: World Heritage Encyclopedia
Language: English
Subject: Discovery and development of HIV-protease inhibitors, Protease inhibitor (pharmacology), Protease inhibitors, Boehringer Ingelheim, Antiretroviral drugs
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
Clinical data
Trade names Aptivus
Licence data EMA:, US FDA:
  • AU: B3
  • US: C (Risk not ruled out)
Legal status
Routes of
Pharmacokinetic data
Bioavailability N/D
Protein binding 99.9%
Metabolism Hepatic
Biological half-life 4.8–6 hours
Excretion Feces (82.3%), urine (4.4%)
CAS Registry Number  Y
ATC code J05
PubChem CID:
DrugBank  Y
ChemSpider  Y
PDB ligand ID TPV (, )
Chemical data
Formula C31H33F3N2O5S
Molecular mass 602.66 g/mol

Tipranavir, or tipranavir disodium, is a nonpeptidic protease inhibitor (PI) manufactured by Boehringer-Ingelheim under the trade name Aptivus. It is administered with ritonavir in combination therapy to treat HIV infection.

Tipranavir has the ability to inhibit the replication of viruses that are resistant to other protease inhibitors and it recommended for patients who are resistant to other treatments. Resistance to tipranavir itself seems to require multiple mutations.[1]

Tipranavir was approved by the Food and Drug Administration (FDA) on June 22, 2005, and was approved for pediatric use on June 24, 2008.[2] Like lopinavir and atazanavir, it is very potent and is effective in salvage therapy for patients with some drug resistance. However, side effects of tipranavir may be more severe than those of other anti-retrovirals. Some side effects include intracranial hemorrhage, hepatitis, hyperglycemia and diabetes mellitus. The drug has also been shown to cause increases in total cholesterol and triglycerides.[3]


  1. ^ Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley M (2005). "Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.". Antiviral Res 68 (1): 27–35.  
  2. ^ "New Aptivus (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients" (Press release).  
  3. ^ "Aptivus® (tipranavir) capsules 250 mg, oral solution 100 mg/mL, Prescribing Information", Boehringer Inhelheim, 2012. Revised April 2012. [2]
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.